articleThe LancetDec 22, 2005Closed access

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

SKStephen K. TyringABAlice B. GottliebKPKim PappKGKen GordonCLCraig L. Leonardi

The University of Texas Health Science Center at Houston · Johnson University · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,067
total citations
FWCI
10.35
Percentile
100%
References
42
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Medicine
  • Placebo
  • Psoriasis Area and Severity Index
  • Etanercept
  • Psoriasis
  • Internal medicine
  • Depression (economics)
  • Physical therapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding